Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Cardio Diagnostics Holdings Inc(CDIO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CDIO
09/18/2026: CDIO (1-star) is currently NOT-A-BUY. Pass it for now.
Cardio Diagnostics Holdings is an early-stage biotechnology company focused on epigenetic, AI-driven cardiovascular diagnostics. Its primary strength lies in its proprietary platform designed to identify heart disease risk, representing a specialized approach to precision medicine. The company's main opportunity is to scale its commercial testing volume through partnerships and broader insurance reimbursement coverage. However, investors must consider the significant execution, liquidity, and competitive risks associated with an early-stage medical diagnostic business facing established industry incumbents. The stock is best suited for growth-oriented investors with high risk tolerance who are closely monitoring clinical adoption, reimbursement progress, and the company's cash runway.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers a high-risk, high-reward profile typical of early-stage biotech, suitable only for those comfortable with speculative growth bets. |
| Momentum investor | Weak fit | The stock has not demonstrated consistent upward price momentum, making it a poor fit for those relying on technical trend signals. |
| Value investor | Weak fit | The lack of earnings and negative cash flow precludes it from traditional value investment criteria. |
| Dividend investor | Weak fit | As a non-dividend-paying company, it does not meet the requirements for income-focused investors. |
| Low-risk investor | Weak fit | The company exhibits high volatility and operational risk, which are incompatible with low-risk investment mandates. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a small-cap biotech stock, CDIO is subject to significant intraday and long-term price swings. |
| Valuation risk | High | Without meaningful earnings, the stock's valuation is often driven by speculative expectations rather than fundamental performance. |
| Competition risk (incumbent labs) | High | Large established providers like LH and DGX have entrenched market access that is difficult to disrupt. |
| Business quality | Medium | The company possesses specialized IP, but its franchise quality is still in the process of being proven via commercial outcomes. |
| Dividend income | Low / none | There is no dividend income expected in the foreseeable future. |
| Execution risk | High | The business relies entirely on successful clinical adoption and obtaining insurance reimbursement. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -78.87% | Avg. Invested days 8 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/18/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.98M USD | Price to earnings Ratio - | 1Y Target Price 60 |
Price to earnings Ratio - | 1Y Target Price 60 | ||
Volume (30-day avg) 49.2K shares | Beta 2.23 | 52 Weeks Range 0.97 - 7.91 | Updated Date 09/18/2026 |
52 Weeks Range 0.97 - 7.91 | Updated Date 09/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.9 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Diagnostic Testing | Revenue generated from performing epigenetic cardiovascular risk tests like PrecisionCHD for healthcare providers. | The company makes money when clinics and hospitals order its specialized tests for patients at risk of heart disease. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 849.91K | Price to Sales(TTM) 413.71 |
Enterprise Value 849.91K | Price to Sales(TTM) 413.71 | ||
Enterprise Value to Revenue 58.82 | Enterprise Value to EBITDA -22.48 | Shares Outstanding 2.96M | Shares Floating 2.84M |
Shares Outstanding 2.96M | Shares Floating 2.84M | ||
Percent Insiders 8.31 | Percent Institutions 6.52 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Cardio Diagnostics Holdings Inc
Exchange NASDAQ | Headquarters Chicago, IL, United States | ||
IPO Launch date 2022-01-14 | Co-Founder, CEO & Director Dr. Meeshanthini V. Dogan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://cdio.ai |
Full time employees 15 | Website https://cdio.ai | ||
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.